id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-288626-7bp92xyo	Spyropoulos, Alex C.	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients	2020-06-30		.txt	text/plain	1272	62	40	OBJECTIVES: The purpose of this study was to evaluate whether extended-duration rivaroxaban reduces the risk of venous and arterial fatal and major thromboembolic events without significantly increasing major bleeding in acutely ill medical patients after discharge. The lower 7.5 mg dose of rivaroxaban used in patients with moderate renal insufficiency was found to be ineffective (8) A meta-analysis of arterial thrombosis (including MI and ischemic stroke) of older studies involving w11,000 medically ill inpatients receiving heparinbased prophylaxis did not find a reduction of these events compared with control subjects (odds ratio: On-treatment includes all data from randomization to 2 days after the last dose of the study drug (inclusive). Our analysis suggests that in at-risk medically ill patients who are discharged from the hospital, extended-duration rivaroxaban at the 10 mg daily dose leads to a significant risk reduction in a composite of fatal and major thromboembolic eventsincluding symptomatic VTE, MI, nonhemorrhagic stroke, and CV death-without a significant increase in major bleeding, compared with placebo.	./cache/cord-288626-7bp92xyo.txt	./txt/cord-288626-7bp92xyo.txt